George A. Fisher Jr.
Publication Details
-
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Invest New Drugs. 2011; (5): 971-7
Overexpression of Bcl-2 is associated with worse prognosis for a number of cancer types. The present study was designed to determine the maximum tolerated dose (MTD) of oblimersen (antisense Bcl-2) and gemcitabine when administered to patients with refractory malignancies.
Help
Trial Administration